Transgene S.A. (Other News To Note).(starts new Phase II trial of MVA-HPV-IL2 anticancer vaccine)

* Transgene SA, of Paris, said it started a third Phase II clinical trial of its anticancer vaccine, MVA-HPV-IL2, this time in the indication of stage 2-3 cervical intra-epithelial neoplasia (CIN2-3). The trial is being conducted at six sites in France on at least 28 women suffering from CIN2-3. CIN are …